The "Epiomic Epidemiology Series: Mucopolysaccharidosis Type Vi Forecast In 30 Major Markets 2018-2028" report has been added to ResearchAndMarkets.com's offering.
This report provides the current prevalent population for MPS VI across 30 Major Markets split by gender and 5-year age cohort. In addition to the current prevalence, the report provides an overview of the risk factors, diagnosis and prognosis of the disease, along with specific variations by geography and ethnicity.
Providing a value-added level of insight from our analysis team, MPS VI patients grouped by disease severity and comorbidities have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Main symptoms and co-morbidities of MPS VI include:
Reasons to buy:
Key Topics Covered:
For more information about this report visit https://www.researchandmarkets.com/research/8bpl68/mucopolysaccharido?w=4
View source version on businesswire.com: https://www.businesswire.com/news/home/20180712005662/en/